Here’s a pattern I’ve seen repeatedly. A medical affairs team builds a publication plan. Timelines align to a congress deadline. Authors are confirmed. A solid first draft is delivered on time. Then the manuscript enters medical-legal-regulatory review, and disappears. Weeks later, it resurfaces covered in tracked changes that contradict each other. Medical pushes for bolder …
Continue reading “Your Publication Plan Isn’t Failing at MLR: It’s Failing at the Outline”
On March 30, 2026, I attended RISE Together: Data Sharing Across the Rare Disease Ecosystem [1] expecting a discussion about the platforms and infrastructure needed to move data more efficiently across systems. Instead, what surfaced over the course of the day was something more fundamental, and more difficult to resolve. The rare disease field is …
Continue reading “When the Data Exists but Doesn’t Travel: Lessons from RISE Together 2026”
On March 25, 2026, I attended MAX: Medical Affairs eXcellence Forum, Canada’s first forum dedicated entirely to medical affairs in biopharma. Organized by Agilis Health and held at the Sheraton Toronto Airport, it brought together 140+ professionals spanning Medical Affairs, Pharma, Clinical Research, Regulatory, and Medical Communications for a full day of candid, high-calibre conversation. …
In the first three articles of this series, we looked at AI where people can see it: reading scans and drafting treatment plans, tutoring students and simulating patients, and even helping design the next generation of medicines. But some of the most profound changes are happening out of sight, in the operating system of the …
Traditional drug development is one of the most expensive and failure-prone endeavors in science. Bringing a new drug to market typically takes over a decade, with cost estimates exceeding two billion dollars and failure rates upwards of 90% [1]. Less than 10% of target drugs even make it to Phase I Trials. AI is now …
Continue reading “AI in Healthcare (3): The Molecule Will Design Itself Now—AI in Drug Discovery”